GLP-1 products, once used for diabetes and now approved to treat obesity, are all the rage with Novo Nordisk A/S and Eli Lilly and Company having made billions just off Wegovy and Mounjaro respectively.
It’s only natural then that any association with such drugs is
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?